Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
43 studies found for:    bexarotene
Show Display Options
Rank Status Study
1 Terminated A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer
Condition: Carcinoma, Non-small-cell Lung
Intervention: Drug: Bexarotene (targretin)
2 Completed Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: Bexarotene
3 Active, not recruiting Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Condition: Refractory Cutaneous T-cell Lymphoma
Intervention: Drug: bexarotene
4 Completed Study of Tarceva and Targretin in Stage I-II Lung Cancer
Condition: Carcinoma, Non-small-cell Lung
Intervention: Drug: erlotinib (Tarceva) and bexarotene (Targretin)
5 Completed Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Decitabine;   Drug: Bexarotene
6 Completed Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract
Condition: Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
Interventions: Drug: Bexarotene (Targretin®);   Drug: Erlotinib (Tarceva™)
7 Completed Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
Condition: Carcinoma, Non-small-cell Lung
Intervention: Drug: erlotinib and bexarotene
8 Active, not recruiting Bexarotene Amyloid Treatment for Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Bexarotene;   Drug: Placebo
9 Active, not recruiting BATTLE Program: Tarceva and Targretin in Patients With NSCLC
Condition: Lung Cancer
Interventions: Drug: Bexarotene;   Drug: Erlotinib
10 Active, not recruiting Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Conditions: Cutaneous T-cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome;   Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions: Drug: Pralatrexate Injection;   Drug: Bexarotene Capsules;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
11 Recruiting Phase I Study of CS-7017 and Bexarotene
Conditions: Solid Tumors;   Lymphoma;   Multiple Myeloma
Intervention: Drug: CS-7017 and Bexarotene
12 Completed Study of Bexarotene in Patients With Acute Myeloid Leukemia
Conditions: AML;   Acute Myeloid Leukemia
Intervention: Drug: Bexarotene
13 Completed Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Bexarotene (Targretin LGD1069);   Drug: bexarotene
14 Not yet recruiting A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
Condition: Alzheimer's Disease
Interventions: Drug: Bexarotene;   Drug: Placebo
15 Completed Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
Condition: Alopecia Areata
Intervention: Drug: Targretin Gel 1%
16 Unknown  Preoperative Bexarotene Treatment for Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: Bexarotene
17 Completed Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Drug: bexarotene;   Drug: gemcitabine hydrochloride
18 Completed Bexarotene in Preventing Breast Cancer in Women at Genetic Risk
Condition: Breast Cancer
Intervention: Drug: bexarotene
19 Completed Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Interventions: Drug: bexarotene;   Device: photopheresis
20 Recruiting A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Conditions: Primary Cutaneous Anaplastic Large Cell Lymphoma,;   Mycosis Fungoides;   Cutaneous T-Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Methotrexate or Bexarotene

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years